Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYnote-240
Journal
Cancer
Journal Volume
127
Journal Issue
6
Pages
865-874
Date Issued
2021
Author(s)
Ryoo B.-Y.
Merle P.
Kulkarni A.S.
Bouattour M.
Lim H.Y.
Breder V.
Edeline J.
Chao Y.
Ogasawara S.
Yau T.
Garrido M.
Chan S.L.
Daniele B.
Norquist J.M.
Chen E.
Siegel A.B.
Zhu A.X.
Finn R.S.
Kudo M.
Abstract
Background: Health-related quality of life (HRQoL) is an important outcome measure and prognostic indicator in hepatocellular carcinoma (HCC). KEYNOTE-240 (NCT02702401) assessed the efficacy and safety of pembrolizumab plus best supportive care (BSC) vers
Subjects
hepatocellular carcinoma; immunotherapy; patient-reported outcome measures; pembrolizumab; quality of life
SDGs
Other Subjects
pembrolizumab; placebo; monoclonal antibody; pembrolizumab; abdominal swelling; adult; advanced cancer; Article; cancer palliative therapy; controlled study; deterioration; drug efficacy; drug safety; European Organization for Research and Treatment of Ca
Publisher
John Wiley and Sons Inc
Type
journal article